Bicycle Therapeutics plc (FRA:50BA)

Bicycle Therapeutics Statistics

Total Valuation

FRA:50BA has a market cap or net worth of EUR 260.78 million. The enterprise value is -269.79 million.

Market Cap	260.78M
Enterprise Value	-269.79M

Important Dates

The next estimated earnings date is Friday, May 1, 2026.

Earnings Date	May 1, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+19.02%
Shares Change (QoQ)	+0.09%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.22
PB Ratio	0.50
P/TBV Ratio	0.50
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	1.45
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	1.26

Financial Position

The company has a current ratio of 11.98, with a Debt / Equity ratio of 0.03.

Current Ratio	11.98
Quick Ratio	11.65
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.07
Interest Coverage	-1,178.96

Financial Efficiency

Return on equity (ROE) is -31.21% and return on invested capital (ROIC) is -21.24%.

Return on Equity (ROE)	-31.21%
Return on Assets (ROA)	-18.13%
Return on Invested Capital (ROIC)	-21.24%
Return on Capital Employed (ROCE)	-36.76%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	214,658
Profits Per Employee	-647,529
Employee Count	288
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

In the past 12 months, FRA:50BA has paid 129,458 in taxes.

Income Tax	129,458
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -42.68% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-42.68%
50-Day Moving Average	4.62
200-Day Moving Average	5.78
Relative Strength Index (RSI)	33.52
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.20

Income Statement

In the last 12 months, FRA:50BA had revenue of EUR 61.82 million and -186.49 million in losses. Loss per share was -2.69.

Revenue	61.82M
Gross Profit	-133.29M
Operating Income	-206.85M
Pretax Income	-186.36M
Net Income	-186.49M
EBITDA	-201.38M
EBIT	-206.85M
Loss Per Share	-2.69

Balance Sheet

The company has 534.96 million in cash and 14.35 million in debt, with a net cash position of 520.61 million.

Cash & Cash Equivalents	534.96M
Total Debt	14.35M
Net Cash	520.61M
Net Cash Per Share	n/a
Equity (Book Value)	519.52M
Book Value Per Share	7.49
Working Capital	533.08M

Cash Flow

In the last 12 months, operating cash flow was -212.65 million and capital expenditures -2.00 million, giving a free cash flow of -214.65 million.

Operating Cash Flow	-212.65M
Capital Expenditures	-2.00M
Depreciation & Amortization	5.56M
Net Borrowing	-145,524
Free Cash Flow	-214.65M
FCF Per Share	n/a

Margins

Gross Margin	-215.60%
Operating Margin	-334.59%
Pretax Margin	-301.45%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:50BA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-19.02%
Shareholder Yield	-19.02%
Earnings Yield	-71.51%
FCF Yield	-82.31%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:50BA has an Altman Z-Score of 1.6 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.6
Piotroski F-Score	2